Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Completed · Phase 2
Conditions studied: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
Key facts
- Study ID
- NCT00002833
- Run by
- M.D. Anderson Cancer Center
- People needed
- 53
- Starts
- 1994-10-01
- Expected to finish
- 2002-04-01
- Last updated by the study team
- 2012-07-30
Who can join
Age: 55 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.